HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer
نویسندگان
چکیده
منابع مشابه
HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer
OBJECTIVE In this study, we evaluate the frequency of HER-2 and HER-3 expression in liver metastases from patients with colorectal cancer (CRLM). We analyzed the potential of HER-2 and HER-3 as therapeutic targets and evaluated their prognostic value. PATIENTS AND METHODS Overall 208 patients with CRLM were enrolled. HER-2 and HER-3 expression were determined in metastatic tissue of diagnosti...
متن کاملEvaluation of Expression of EGFR, HER-2 and COX-2 in Colorectal Cancer
Background and objective: EGFR and HER-2 are two members of ERbB/HER family of Type I Transmembrane growth factor receptors. Cox2 is an enzyme responsible for the conversion of arachidonic acid to prostaglandins, which has a major role in angiogenesis and can modelate tumor growth. The aim of this study was to determine the level of expression of EGFR, HER-2 and Cox2 in colorectd cancer. Mater...
متن کاملClinical role of HER-2/neu expression in colorectal cancer.
PURPOSE To evaluate the HER-2/neu expression and its relationship with clinicopathological parameters and prognosis in colorectal cancer patients. METHODS A total of 51 colorectal cancer patients who underwent resection with curative intent from January 2005 to March 2006 were included in this study. Patients were regularly followed up and survival data were obtained as of as April 2011. HER-...
متن کاملHER-3 expression in HER-2-amplified breast carcinoma
AIM OF THE STUDY To determine whether the expression of HER-3 influences the survival of HER-2 positive patients with breast cancer (BC). MATERIAL AND METHODS In the present work, the expression of HER-3 in a group of 35 HER-2 positive patients with BC was studied by performing immunohistochemistry (IHC) in formalin-fixed paraffin embedded tissues. RESULTS Higher HER-3 status if estimated b...
متن کاملExpression of heregulin, phosphorylated HER-2, HER-3 and HER-4 in HER-2 negative breast cancers.
A significant number of HER-2 amplified breast cancers is effectively treated by trastuzumab and further shows receptor-enhanced chemosensitivity. Recent studies have postulated transactivation of HER-2 also in tumors expressing phosphorylated/activated HER-2 (pHER-2) and of the HER-3/HER-4 ligand heregulin (HRG), independent of HER-2 amplification. As a consequence, a subset of tumors without ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Oncotarget
سال: 2015
ISSN: 1949-2553
DOI: 10.18632/oncotarget.3527